This website uses cookies to enhance the user experience.
21st logo
||
A

ALEXION PHARMA NORDICS AB NUF996 890 465

Purchase and sale
Norwegian division of foreign business enterprise
c/o CSC (Norway) AS Bryggegata 6 0250 OSLO, Norge

ALEXION PHARMA NORDICS AB NUF

Operating
Kommersialisering av produkter for behandling av humanpasienter og ulike typer av helseprodukter. Direkte eller indirekte distribusjon, markedsføring og sikkerhetsovervåkning av terapeutiske produkter. Å registrere, søke eller medsøke om, kjøp, beskytte, forlenge, fornye, samt generell anvendelse av immaterielle rettigheter, lisenser, varemerking, markedsføring av nevnte tjenester ovenfor. Samt øvrig beslektet virksomhet.

Keywords

pharmaceuticalshospital equipmentorthopedic articles

Organization

CEO
HJ

Hans Jacob Julius Brun1977

Years since formation
15 years
since Jun 1, 2011
Type
Norwegian division of foreign business enterprise
VAT registered
Yes
Number of employees
0

Financials

Total operating income 2025
21,441,091
NOK
Annual total result 2025
1,136,753
NOK
Total equity 2025
19,250,764
NOK
Last update: Aug 11, 2026

Management

Management / administration

NameRoleShares
HJ

Hans Jacob Julius Brun

1977

Managing Director/CEO-

Board

NameRoleShares
A
ALEXION PHARMA NORDICS AB
Information about the Company in the Home Country-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Auditor-
C
CSC ACCOUNTING (NORWAY) AS
Accountant-
E
ENORA AS
Accountant-
Last update: Dec 12, 2025

Ownership

No available data

Financials

in NOK

Summary

Year20252024202320222021
Total operating income
21,441,091
20,393,288
80,681,040
108,369,854
88,743,367
Annual Total Result
1,136,753
790,055
2,099,418
2,122,116
2,827,048
Total assets
22,023,262
38,696,983
20,171,795
40,583,384
35,517,953
Total liabilities
2,772,498
20,582,971
2,847,841
25,358,846
22,415,532
Total equity
19,250,764
18,114,012
17,323,955
15,224,538
13,102,422

P&L

Year20252024202320222021
Total operating income
21,441,091
20,393,288
80,681,040
108,369,854
88,743,367
Total operating costs
20,795,522
19,766,291
78,579,150
105,897,768
85,082,013
Operating result
645,569
626,997
2,101,890
2,472,086
3,661,355
Financial income/costs
811,244
521,482
590,497
251,075
-115,400
Profit before tax
1,456,813
1,148,479
2,692,387
2,723,160
3,545,955
Total tax & extraordinary income/cost
320,060
358,424
592,969
601,044
718,907
Annual Total Result
1,136,753
790,055
2,099,418
2,122,116
2,827,048

Balance overview

Year20252024202320222021
Total fixed assets
43,499
117,400
192,485
253,829
321,143
Total current assets
21,979,763
38,579,583
19,979,311
40,329,555
35,196,810
Total assets
22,023,262
38,696,983
20,171,795
40,583,384
35,517,953
Short term debt
2,772,498
20,582,971
2,847,841
25,358,846
22,415,532
Long term debt
0
0
0
0
0
Total liabilities
2,772,498
20,582,971
2,847,841
25,358,846
22,415,532
Contributed capital
0
0
0
0
0
Retained earnings
19,250,764
18,114,012
17,323,955
15,224,538
13,102,422
Total equity
19,250,764
18,114,012
17,323,955
15,224,538
13,102,422
Total equity and liabilities
22,023,262
38,696,983
20,171,795
40,583,384
35,517,953

Classification

21st company classification
BETA
Industrial large enterprise
Category
Type of organization
Norwegian division of foreign business enterprise
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
G
Main industrial area
Wholesale and retail trade; repair of motor vehicles and motorcycles
46
Activity
Wholesale trade, except of motor vehicles and motorcycles
46.4
Main industrial group
Wholesale of household goods
46.46
Industrial group
Wholesale of pharmaceutical goods
46.460
Industrial group
Wholesale of pharmaceutical goods